Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations

J Investig Allergol Clin Immunol. 2011;21(6):422-41; quiz 442-3.

Abstract

Background: There are no previous Spanish guidelines or consensus statements on bradykinin-induced angioedema.

Aim: To draft a consensus statement on the management and treatment of angioedema mediated by bradykinin in light of currently available scientific evidence and the experience of experts. This statement will serve as a guideline to health professionals.

Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema, a working group of the Spanish Society of Allergology and Clinical Immunology. A review was conducted of scientific papers on different types of bradykinin-induced angioedema (hereditary and acquired angioedema due to C1 inhibitor deficiency, hereditary angioedema related to estrogens, angioedema induced by angiotensin-converting enzyme inhibitors). Several discussion meetings were held to reach the consensus.

Results: Treatment approaches are discussed, and the consensus reached is described. Specific situations are addressed, namely, pregnancy, contraception, travelling, blood donation, and organ transplantation.

Conclusions: A review of and consensus on treatment of bradykinin-induced angioedema is presented.

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Angioedema* / diagnosis
  • Angioedema* / metabolism
  • Angioedema* / therapy
  • Bradykinin / antagonists & inhibitors*
  • Bradykinin / metabolism
  • Humans
  • Prognosis

Substances

  • Bradykinin